Stay updated with breaking news from Nasdaq Fdmt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the nine research firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) saw a significant drop in short interest in the month of April. As of April 30th, there was short interest totalling 2,840,000 shares, a drop of 10.1% from the April 15th total of 3,160,000 shares. Based on an average trading volume of 510,400 shares, the days-to-cover ratio […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) gapped down prior to trading on Tuesday . The stock had previously closed at $17.82, but opened at $17.23. 4D Molecular Therapeutics shares last traded at $17.51, with a volume of 51,817 shares trading hands. Analysts Set New Price Targets FDMT has been the subject of a […]
Denali Advisors LLC purchased a new position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) in the 4th quarter, HoldingsChannel reports. The firm purchased 2,000 shares of the company’s stock, valued at approximately $44,000. Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Belpointe Asset Management […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Rating) – Stock analysts at SVB Leerink upped their Q2 2023 earnings per share estimates for shares of 4D Molecular Therapeutics in a report issued on Wednesday, May 10th. SVB Leerink analyst M. Foroohar now expects that the company will earn ($0.61) per share for the quarter, up […]